Logo image of MYNZ

MAINZ BIOMED NV (MYNZ) Stock Fundamental Analysis

NASDAQ:MYNZ - Nasdaq - NL0015000LC2 - Common Stock - Currency: USD

5.07  -0.16 (-3.06%)

After market: 5.1 +0.03 (+0.59%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MYNZ. MYNZ was compared to 571 industry peers in the Biotechnology industry. MYNZ may be in some trouble as it scores bad on both profitability and health. MYNZ is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MYNZ had negative earnings in the past year.
MYNZ had a negative operating cash flow in the past year.
In the past 5 years MYNZ always reported negative net income.
MYNZ had a negative operating cash flow in each of the past 5 years.
MYNZ Yearly Net Income VS EBIT VS OCF VS FCFMYNZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -311.04%, MYNZ is doing worse than 94.46% of the companies in the same industry.
Industry RankSector Rank
ROA -311.04%
ROE N/A
ROIC N/A
ROA(3y)-139.16%
ROA(5y)-127.77%
ROE(3y)-393.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYNZ Yearly ROA, ROE, ROICMYNZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

1.3 Margins

With a decent Gross Margin value of 56.92%, MYNZ is doing good in the industry, outperforming 77.86% of the companies in the same industry.
In the last couple of years the Gross Margin of MYNZ has grown nicely.
MYNZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.46%
GM growth 5YN/A
MYNZ Yearly Profit, Operating, Gross MarginsMYNZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K -5K

More info and screens

0

2. Health

2.1 Basic Checks

MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
MYNZ has less shares outstanding than it did 1 year ago.
The debt/assets ratio for MYNZ is higher compared to a year ago.
MYNZ Yearly Shares OutstandingMYNZ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M
MYNZ Yearly Total Debt VS Total AssetsMYNZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -20.43, we must say that MYNZ is in the distress zone and has some risk of bankruptcy.
MYNZ's Altman-Z score of -20.43 is on the low side compared to the rest of the industry. MYNZ is outperformed by 86.43% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.43
ROIC/WACCN/A
WACC6.96%
MYNZ Yearly LT Debt VS Equity VS FCFMYNZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 0.24 indicates that MYNZ may have some problems paying its short term obligations.
MYNZ has a Current ratio of 0.24. This is amonst the worse of the industry: MYNZ underperforms 96.61% of its industry peers.
A Quick Ratio of 0.19 indicates that MYNZ may have some problems paying its short term obligations.
MYNZ has a worse Quick ratio (0.19) than 97.14% of its industry peers.
Industry RankSector Rank
Current Ratio 0.24
Quick Ratio 0.19
MYNZ Yearly Current Assets VS Current LiabilitesMYNZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for MYNZ have decreased strongly by -3381.64% in the last year.
The Revenue has grown by 68.96% in the past year. This is a very strong growth!
The Revenue has been growing by 22.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-3381.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3487.15%
Revenue 1Y (TTM)68.96%
Revenue growth 3Y22.26%
Revenue growth 5YN/A
Sales Q2Q%110%

3.2 Future

The Earnings Per Share is expected to grow by 14.86% on average over the next years. This is quite good.
Based on estimates for the next years, MYNZ will show a very strong growth in Revenue. The Revenue will grow by 156.06% on average per year.
EPS Next Y63.45%
EPS Next 2Y36.42%
EPS Next 3Y25.15%
EPS Next 5Y14.86%
Revenue Next Year12.87%
Revenue Next 2Y15.41%
Revenue Next 3Y7.23%
Revenue Next 5Y156.07%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MYNZ Yearly Revenue VS EstimatesMYNZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
MYNZ Yearly EPS VS EstimatesMYNZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MYNZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MYNZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYNZ Price Earnings VS Forward Price EarningsMYNZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYNZ Per share dataMYNZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

MYNZ's earnings are expected to grow with 25.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.42%
EPS Next 3Y25.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MYNZ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAINZ BIOMED NV

NASDAQ:MYNZ (3/3/2025, 8:00:00 PM)

After market: 5.1 +0.03 (+0.59%)

5.07

-0.16 (-3.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2024-11-11/bmo
Earnings (Next)04-07 2025-04-07/amc
Inst Owners11.06%
Inst Owner ChangeN/A
Ins Owners4.07%
Ins Owner ChangeN/A
Market Cap11.26M
Analysts43.33
Price Target14.28 (181.66%)
Short Float %1.66%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)600%
PT rev (3m)600%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2156.41%
EPS NY rev (1m)27.03%
EPS NY rev (3m)-1868%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.69%
Revenue NY rev (1m)-0.82%
Revenue NY rev (3m)-11.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.57
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-48.05
EYN/A
EPS(NY)-6.68
Fwd EYN/A
FCF(TTM)-9.06
FCFYN/A
OCF(TTM)-8.7
OCFYN/A
SpS0.4
BVpS-1.86
TBVpS-3.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -311.04%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.92%
FCFM N/A
ROA(3y)-139.16%
ROA(5y)-127.77%
ROE(3y)-393.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.46%
GM growth 5YN/A
F-Score3
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 88.5%
Cap/Sales 89.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.24
Quick Ratio 0.19
Altman-Z -20.43
F-Score3
WACC6.96%
ROIC/WACCN/A
Cap/Depr(3y)140.47%
Cap/Depr(5y)87.62%
Cap/Sales(3y)113.34%
Cap/Sales(5y)68.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3381.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3487.15%
EPS Next Y63.45%
EPS Next 2Y36.42%
EPS Next 3Y25.15%
EPS Next 5Y14.86%
Revenue 1Y (TTM)68.96%
Revenue growth 3Y22.26%
Revenue growth 5YN/A
Sales Q2Q%110%
Revenue Next Year12.87%
Revenue Next 2Y15.41%
Revenue Next 3Y7.23%
Revenue Next 5Y156.07%
EBIT growth 1Y-0.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-104.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-102.2%
OCF growth 3YN/A
OCF growth 5YN/A